Characterization and Formulation Screening of mAb and Antibody-Drug Conjugates (ADCs) by High-throughput DLS

G. Ratnaswamy,A. Seneviratne,Aileen La
Abstract:Antibody-Drug Conjugates (ADCs) are important biotherapeutic candidates that combine highly potent cytoxic drugs with monoclonal antibodies (mAb) for targeted drug delivery in the treatment of cancer or neurodegenerative disorders. However, while the underlying mAb may be a relatively stable molecule, the addition of the drug and linker often destabilizes the protein or adds undesirable intermolecular interactions, so that ADC biotherapeutics are heavily prone to aggregation. Uncontrolled aggregation can lead to a loss in clinical efficacy in vivo or, in extreme cases, invoke a serious immunogenic response. Monitoring stability during formulation is therefore essential to ensure that ADC compounds meet commercial, performance and safety targets.
Chemistry,Medicine
What problem does this paper attempt to address?